Investors

Financials & Filings

Filing date Form Description Filing Group View
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
PRRN14A

Non-management revised preliminary proxy soliciting materials

Proxy Filings
UPLOAD

UPLOAD

Other
10-K/A

Amendment to a previously filed 10-K

Annual Filings
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
SC 13D/A

An amendment to a SC 13D filing

Other
DFAN14A

Additional proxy soliciting materials filed by non-management

Proxy Filings
PREC14A

Preliminary proxy statement containing contested solicitations

Proxy Filings
SC 13D/A

An amendment to a SC 13D filing

Other
DFAN14A

Additional proxy soliciting materials filed by non-management

Proxy Filings
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.